340 related articles for article (PubMed ID: 11408519)
1. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
Giuffrida A; Beltramo M; Piomelli D
J Pharmacol Exp Ther; 2001 Jul; 298(1):7-14. PubMed ID: 11408519
[TBL] [Abstract][Full Text] [Related]
2. Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors.
Kelley BG; Thayer SA
Eur J Pharmacol; 2004 Aug; 496(1-3):33-9. PubMed ID: 15288572
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
[TBL] [Abstract][Full Text] [Related]
4. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of anandamide hypotension by the transport inhibitor, AM404.
Calignano A; La Rana G; Beltramo M; Makriyannis A; Piomelli D
Eur J Pharmacol; 1997 Oct; 337(1):R1-2. PubMed ID: 9389389
[TBL] [Abstract][Full Text] [Related]
7. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.
Nicolussi S; Viveros-Paredes JM; Gachet MS; Rau M; Flores-Soto ME; Blunder M; Gertsch J
Pharmacol Res; 2014 Feb; 80():52-65. PubMed ID: 24412246
[TBL] [Abstract][Full Text] [Related]
8. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
9. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
Reggio PH; Traore H
Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes.
Shivachar AC
Biochem Pharmacol; 2007 Jun; 73(12):2004-11. PubMed ID: 17445778
[TBL] [Abstract][Full Text] [Related]
11. Functional role of high-affinity anandamide transport, as revealed by selective inhibition.
Beltramo M; Stella N; Calignano A; Lin SY; Makriyannis A; Piomelli D
Science; 1997 Aug; 277(5329):1094-7. PubMed ID: 9262477
[TBL] [Abstract][Full Text] [Related]
12. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor.
Beltramo M; de Fonseca FR; Navarro M; Calignano A; Gorriti MA; Grammatikopoulos G; Sadile AG; Giuffrida A; Piomelli D
J Neurosci; 2000 May; 20(9):3401-7. PubMed ID: 10777802
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid system as a target for therapeutic drugs.
Piomelli D; Giuffrida A; Calignano A; Rodríguez de Fonseca F
Trends Pharmacol Sci; 2000 Jun; 21(6):218-24. PubMed ID: 10838609
[TBL] [Abstract][Full Text] [Related]
14. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
Lang W; Qin C; Lin S; Khanolkar AD; Goutopoulos A; Fan P; Abouzid K; Meng Z; Biegel D; Makriyannis A
J Med Chem; 1999 Mar; 42(5):896-902. PubMed ID: 10072686
[TBL] [Abstract][Full Text] [Related]
15. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
16. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.
Giuffrida A; Rodriguez de Fonseca F; Nava F; Loubet-Lescoulié P; Piomelli D
Eur J Pharmacol; 2000 Nov; 408(2):161-8. PubMed ID: 11080522
[TBL] [Abstract][Full Text] [Related]
17. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
Deutsch DG; Lin S; Hill WA; Morse KL; Salehani D; Arreaza G; Omeir RL; Makriyannis A
Biochem Biophys Res Commun; 1997 Feb; 231(1):217-21. PubMed ID: 9070252
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.
López-Rodríguez ML; Viso A; Ortega-Gutiérrez S; Fowler CJ; Tiger G; de Lago E; Fernández-Ruiz J; Ramos JA
J Med Chem; 2003 Apr; 46(8):1512-22. PubMed ID: 12672252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
